Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.790
+0.125 (7.51%)
Sep 5, 2025, 4:00 PM - Market closed
Traws Pharma Revenue
Traws Pharma had revenue of $2.73M in the quarter ending June 30, 2025, with 4,694.74% growth. This brings the company's revenue in the last twelve months to $2.90M, up 1,184.51% year-over-year. In the year 2024, Traws Pharma had annual revenue of $226.00K.
Revenue (ttm)
$2.90M
Revenue Growth
+1,184.51%
P/S Ratio
2.74
Revenue / Employee
$414,714
Employees
7
Market Cap
12.64M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 226.00K | - | - |
Dec 31, 2023 | 226.00K | - | - |
Dec 31, 2022 | 226.00K | - | - |
Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TRAW News
- 18 days ago - Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - GlobeNewsWire
- 22 days ago - Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - GlobeNewsWire
- 4 weeks ago - Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewsWire
- 2 months ago - Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions - GlobeNewsWire
- 3 months ago - Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib - GlobeNewsWire
- 3 months ago - Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness - GlobeNewsWire
- 4 months ago - Traws Pharma Reports First Quarter 2025 Results and Business Highlights - GlobeNewsWire